{
    "clinical_study": {
        "@rank": "107392", 
        "arm_group": {
            "arm_group_label": "wavefront-guided LASIK", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this clinical trial is to demonstrate that wavefront-guided LASIK is safe and\n      effective for the correction of myopic refractive errors."
        }, 
        "brief_title": "Safety and Effectiveness of Wavefront-Guided LASIK Corrections of Myopic Refractive Errors", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Myopia", 
        "condition_browse": {
            "mesh_term": [
                "Myopia", 
                "Refractive Errors"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  18 years of age or greater\n\n          -  Best Spectacle Corrected Visual Acuity (BSCVA) of 20/20 or better\n\n          -  Uncorrected visual acuity (UCVA) of 20/40 or worse\n\n          -  Less than 0.75D difference between cycloplegic and manifest refraction sphere.\n\n          -  Demonstration of refractive stability\n\n          -  Anticipated post-operative stromal bed thickness of at least 250 microns\n\n          -  Willing and capable of returning for follow-up examinations for the duration of the\n             study.\n\n        Exclusion Criteria:\n\n          -  Women who are pregnant, breast-feeding, or intend to become pregnant over the course\n             of the study\n\n          -  Concurrent use of topical or systemic medications that may impair healing\n\n          -  History of any medical conditions that could affect wound healing\n\n          -  History of prior intraocular or corneal surgery, active ophthalmic disease, or other\n             ocular abnormality\n\n          -  Evidence of keratoconus, corneal irregularity, or abnormal topography in the\n             operative eye(s)\n\n          -  Known sensitivity or inappropriate responsiveness to any of the medications used in\n             the post-operative course"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "345", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 9, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01663363", 
            "org_study_id": "STAR-110-IDMY"
        }, 
        "intervention": {
            "arm_group_label": "wavefront-guided LASIK", 
            "description": "Surgeons will perform wavefront-guided LASIK based upon measurement obtained with the iDesign System", 
            "intervention_name": "LASIK correction of myopic refractive errors", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "refractive", 
            "LASIK"
        ], 
        "lastchanged_date": "March 11, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Milpitas", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "95035"
                }, 
                "name": "Contact Abbott Medical Optics for locations"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Prospective Study to Evaluate the Safety and Effectiveness of Wavefront-Guided LASIK Correction of Myopic Refractive Errors With the iDesign Advanced Wavescan Studio\u2122 System and Star S4IR\u2122 Excimer Laser", 
        "overall_official": {
            "affiliation": "Abbott Medical Optics", 
            "last_name": "Kendra Hileman, PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "<5% of eyes with a loss of > 2 lines of Best Spectacle Corrected Visual Acuity", 
            "measure": "Line loss for Best Corrected Visual Acuity (BSCVA)", 
            "safety_issue": "Yes", 
            "time_frame": "6 Months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01663363"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "85% of eyes with uncorrected visual acuity of 20/40 or better", 
            "measure": "Uncorrected Visual Acuity (VA) 20/40 or better", 
            "safety_issue": "No", 
            "time_frame": "6 Months"
        }, 
        "source": "Abbott Medical Optics", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Abbott Medical Optics", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}